Amorfix arranges private placement of up to $1-million

Amorfix Life Sciences (TSX:AMF) intends to complete, subject to regulatory approval, a non-brokered private placement of between approximately 2,222,222 units and 4,444,444 units at a price of 22.5 cents a unit for gross proceeds of $500,000 to $1 million. Each unit will consist of one common share of Amorfix and one common share purchase warrant, [...]

Amorfix turnaround builds broad pipeline

What a difference a year makes. In 2010, Amorfix Life Sciences (TSX:AMF) pulled the plug on its lead blood test to detect the human variant of Creutzfeldt-Jakob disease, thereby halving its stock price and prompting a management shakeup. Today, Amorfix has built an innovative, early-stage product pipeline, including diagnostics and therapeutics for neurodegenerative diseases and [...]

Amorfix produces high-affinity antibodies to DSEs

Amorfix Life Sciences (TSX:AMF), together with its partner, has produced high-affinity antibodies to prion protein disease-specific epitopes (DSEs), which bind preferentially to several cancer primary cells and tumour cell lines, but not normal cells. “This represents a significant milestone for our cancer therapeutic antibody program,” CEO Dr. Robert Gundel said in a statement. “The generation [...]

Amorfix and Epitomics to develop monoclonal antibodies

Amorfix Life Sciences (TSX:AMF) and Epitomics of California and China have entered into an agreement to develop high-affinity monoclonal antibodies against a number of targets for cancer. Amorfix has identified several disease specific epitopes on misfolded proteins with its ProMIS platform discovery technology, which will be used by Epitomics to generate highly specific monoclonal antibodies. [...]